Compare Merck & Co., Inc. (MRK) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Workiva Inc — how do they compare? Merck & Co., Inc. trades at $142.58 (market cap $351.28B), while Workiva Inc trades at $75.4 (market cap $4.01B). The key difference: Merck & Co., Inc. is far larger — about 87.6× Workiva Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Workiva Inc for 21 Days on average.
| MRK | WK | |
|---|---|---|
Market Cap | $351.28B | $4.01B |
Volume | 7,969,665 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $156.43 | $93.31 |
52-Week Low | $82.49 | $44.31 |
Typical Hold Time | 98 Days | 21 Days |
Enterprise Value | $398.04B | $3.99B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
WK trades at $71.53, up 1.95% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and analyst consensus of $86 price target. Revenue grew to $966M in 2026 with net income turning positive at $47M. Recent news highlights AI innovation and inclusion in major indices, supporting positive sentiment.
The outlook remains positive with 89% analyst buy ratings and improving profitability. Key risks include high valuation multiples (P/E 87.7) and competitive pressures in the regulatory software space. The stock offers growth potential but requires monitoring of execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
